Cyclo Therapeutics, Inc.
CYTHDelisted Mar 26, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000922247
Cyclo Therapeutics, Inc. was delisted on Mar 26, 2025; its insiders filed their last Form 4 on Mar 3, 2025; 22 institutions reported holding it in 13F filings for Q4 2024, worth $1.33M in total; no superinvestor held it.
13F holders, Q1 2024
Institutional positions in Cyclo Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −1 vs. Q4 2023
- Shares held
- 2.16M
- +863.4K (+66.4%) vs. Q4 2023
- Total value
- $3.01M
- +$944.3K (+45.8%) vs. Q4 2023
- New holders
- 4
- 11 more added
- Sold out
- 5
- 3 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CYTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 22 | $1.33M |
| Q3 2024 | 19 | $1.80M |
| Q2 2024 | 22 | $2.84M |
| Q1 2024 | 22 | $3.01M |
| Q4 2023 | 23 | $2.06M |
| Q3 2023 | 17 | $682.7K |
| Q2 2023 | 14 | $725.2K |
| Q1 2023 | 16 | $820.2K |
| Q4 2022 | 15 | $1.83M |
| Q3 2022 | 12 | $768.0K |
| Q2 2022 | 13 | $794.0K |
| Q1 2022 | 13 | $1.38M |
| Q4 2021 | 15 | $1.71M |
| Q3 2021 | 13 | $2.23M |
| Q2 2021 | 12 | $2.70M |
| Q1 2021 | 9 | $585.0K |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Cyclo Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EPIQ Capital Group, LLC | 853,815 | $1.19M | 0.47% | +853,815 | New |
| Founders Fund V Management, LLC | 480,708 | $668.2K | 61.13% | 00.0% | Unchanged |
| Vanguard Group Inc | 396,658 | $551.4K | 0.00% | +41,435+11.7% | Added |
| Geode Capital Management, LLC | 159,749 | $222.1K | 0.00% | +7,672+5.0% | Added |
| Founders Fund VI Management, LLC | 110,023 | $152.9K | 57.89% | 00.0% | Unchanged |
| State Street Corp | 39,530 | $54.9K | 0.00% | +50.0% | Added |
| BlackRock Inc. | 37,126 | $51.6K | 0.00% | −11,318−23.4% | Reduced |
| Northern Trust Corp | 21,741 | $30.2K | 0.00% | +4,288+24.6% | Added |
| Renaissance Technologies LLC | 21,756 | $30.0K | 0.00% | +21,756 | New |
| Wealth Enhancement Advisory Services, LLC | 20,400 | $28.4K | 0.00% | +1,887+10.2% | Added |
| Tower Research Capital LLC (TRC) | 6,582 | $9.15K | 0.00% | +711+12.1% | Added |
| UBS Group AG | 4,828 | $6.71K | 0.00% | +4,828 | New |
| Wells Fargo & Company | 4,565 | $6.34K | 0.00% | +2,179+91.3% | Added |
| Princeton Global Asset Management LLC | 3,766 | $5.24K | 0.00% | +3,466+1,155.3% | Added |
| Morgan Stanley | 1,037 | $1.44K | 0.00% | +624+151.1% | Added |
| Royal Bank of Canada | 746 | $1.00K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 153 | $213 | 0.00% | +135+750.0% | Added |
| Steward Partners Investment Advisory, LLC | 90 | $125 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 67 | $93 | 0.00% | −533−88.8% | Reduced |
| Catalyst Funds Management Pty Ltd | 67 | $93 | 0.00% | +67 | New |
| Bank of America Corp | 27 | $38 | 0.00% | +13+92.9% | Added |
| Qube Research & Technologies Ltd | 21 | $29 | 0.00% | −100−82.6% | Reduced |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −54,018−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −10,696−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −113−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −2,527−100.0% | Sold out |